Acrobiosystems Co.Ltd.
Acrobiosystems Co.,Ltd. engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and scientific research institutions. The company has a collaboration with Diagnostic Biochips Inc for neurological drug discovery and commercialization. The company was founded in 2010 and is based in Beijing, China.
Acrobiosystems Co.Ltd. (301080) - Total Liabilities
Latest total liabilities as of June 2025: CN¥268.57 Million CNY
Based on the latest financial reports, Acrobiosystems Co.Ltd. (301080) has total liabilities worth CN¥268.57 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Acrobiosystems Co.Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how Acrobiosystems Co.Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Acrobiosystems Co.Ltd. Competitors by Total Liabilities
The table below lists competitors of Acrobiosystems Co.Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Quanta Storage
TWO:6188
|
Taiwan | NT$5.08 Billion |
|
Xiamen Jihong Package Technology Ltd
SHE:002803
|
China | CN¥1.42 Billion |
|
Gas Malaysia Bhd
KLSE:5209
|
Malaysia | RM2.13 Billion |
|
Shanghai Kaibao Pharmaceutical
SHE:300039
|
China | CN¥412.55 Million |
|
Family Zone Cyber Safety Limited
PINK:FMZNF
|
USA | $175.38 Million |
|
Qinhuangdao Port Co Ltd
SHG:601326
|
China | CN¥6.83 Billion |
|
SP Setia Bhd
KLSE:8664
|
Malaysia | RM11.09 Billion |
|
Shandong Sinobioway Biomedicine Co Ltd
SHE:002581
|
China | CN¥221.51 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Acrobiosystems Co.Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Acrobiosystems Co.Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Acrobiosystems Co.Ltd. (2019–2024)
The table below shows the annual total liabilities of Acrobiosystems Co.Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥303.89 Million | +34.93% |
| 2023-12-31 | CN¥225.22 Million | +34.66% |
| 2022-12-31 | CN¥167.25 Million | +112.15% |
| 2021-12-31 | CN¥78.84 Million | +90.98% |
| 2020-12-31 | CN¥41.28 Million | +156.04% |
| 2019-12-31 | CN¥16.12 Million | -- |